A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Altered mRNA translation is one of the effects exerted by the BCR/ABL oncoprotein in the blast crisis phase of chronic myelogenous leukemia (CML). Here, we report that in BCR/ABL+ cell lines and in patient-derived CML blast crisis mononuclear and CD34+ cells, p210(BCR/ABL) increases expression and activity of the transcriptional-inducer and translational-regulator heterogeneous nuclear ribonucleoprotein K (hnRNP K or HNRPK) in a dose- and kinase-dependent manner through the activation of the MAPK(ERK1/2) pathway. Furthermore, HNRPK down-regulation and interference with HNRPK translation-but not transcription-regulatory activity impairs cytokine-independent proliferation, clonogenic potential, and in vivo leukemogenic activity of BCR/ABL-expressing myeloid 32Dcl3 and/or primary CD34+ CML-BC patient cells. Mechanistically, we demonstrate that decreased internal ribosome entry site (IRES)-dependent Myc mRNA translation accounts for the phenotypic changes induced by inhibition of the BCR/ABL-ERK-dependent HNRPK translation-regulatory function. Accordingly, MYC protein but not mRNA levels are increased in the CD34+ fraction of patients with CML in accelerated and blastic phase but not in chronic phase CML patients and in the CD34+ fraction of marrow cells from healthy donors. Thus, BCR/ABL-dependent enhancement of HNRPK translation-regulation is important for BCR/ABL leukemogenesis and, perhaps, it might contribute to blast crisis transformation.

[1]  R. Kurzrock,et al.  Molecular characteristics of chronic myelogenous leukemia in blast crisis. , 1987, Cancer genetics and cytogenetics.

[2]  R. V. van Etten,et al.  Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling , 2001, The EMBO journal.

[3]  T. Naruse,et al.  Detection of c-myc oncogene amplification in a CML blastic phase patient with double minute chromosomes. , 1996, Leukemia research.

[4]  V. Gopal,et al.  Abnormal regulation of the myc gene in myeloid leukemia , 1992, Medical oncology and tumor pharmacotherapy.

[5]  M. Mandal,et al.  Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function* , 2001, The Journal of Biological Chemistry.

[6]  Andrea Urbani,et al.  A proteomic investigation into etoposide chemo‐resistance of neuroblastoma cell lines , 2005, Proteomics.

[7]  G. Dreyfuss,et al.  Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins , 1995, Molecular and cellular biology.

[8]  J. Melo,et al.  Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia , 2005, Oncogene.

[9]  S. Gribble,et al.  Genomic imbalances in CML blast crisis: 8q24.12–q24.13 Segment identified as a common region of over‐representation , 2003, Genes, chromosomes & cancer.

[10]  G. Zon,et al.  C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. , 1995, Cancer research.

[11]  M. Caligiuri,et al.  BCR/ABL activates mdm2 mRNA translation via the La antigen. , 2003, Cancer cell.

[12]  F. Turturro,et al.  BCR/ABL, mRNA translation and apoptosis , 2005, Cell Death and Differentiation.

[13]  M. Nagano,et al.  Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation , 1998, Oncogene.

[14]  M. Roussel,et al.  Expression of c-Myc in Response to Colony-stimulating Factor-1 Requires Mitogen-activated Protein Kinase Kinase-1* , 1999, The Journal of Biological Chemistry.

[15]  L. Chan.  The Molecular Biology of Chronic Myeloid Leukaemia , 1998 .

[16]  Bulent Ozpolat,et al.  Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. , 2004, Blood.

[17]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[18]  H. Sato,et al.  Assessment of c-myc expression in individual leukemic cells. , 1988, Leukemia research.

[19]  M. Zvelebil,et al.  Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons , 2004, Oncogene.

[20]  Y. Yamashita,et al.  Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells , 2001, Oncogene.

[21]  B. Calabretta,et al.  Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Jerzy Ostrowski,et al.  hnRNP K: One protein multiple processes , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  Anne E Willis,et al.  Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo , 2003, Oncogene.

[24]  D. Cortez,et al.  The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells , 1997, Oncogene.

[25]  A. Gingras,et al.  mTOR signaling to translation. , 2004, Current topics in microbiology and immunology.

[26]  G. Dreyfuss,et al.  The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein , 1997, The EMBO journal.

[27]  David Levens,et al.  Heterogeneous nuclear ribonucleoprotein K is a transcription factor , 1996, Molecular and cellular biology.

[28]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[29]  T. Lion,et al.  Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. , 1995, Blood.

[30]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2 , 2002, Nature Genetics.

[31]  R. Arlinghaus,et al.  Signal transduction pathways in Bcr-Abl transformed cells. , 2004, Cancer treatment and research.

[32]  Melo Jv.  The molecular biology of chronic myeloid leukaemia. , 1996 .

[33]  R. Kurzrock,et al.  Effect of differentiation‐inducing agents on oncogene expression in a chronic myelogenous leukemia cell line , 1988, Cancer.

[34]  P. Pandolfi,et al.  62 dok , a Negative Regulator of Ras and Mitogen-activated Protein Kinase ( MAPK ) Activity , Opposes Leukemogenesis by p 210 bcr-abl , 2001 .

[35]  D. Cortez,et al.  Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis , 1995, Molecular and cellular biology.

[36]  P. Pandolfi,et al.  P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl , 2001, The Journal of experimental medicine.

[37]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[38]  S. Liebhaber,et al.  The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. , 2002, RNA.

[39]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[40]  R. Salgia,et al.  Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. , 1993, Experimental hematology.

[41]  B. Calabretta,et al.  TLS/FUS, a pro‐oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL‐mediated leukemogenesis , 1998, The EMBO journal.

[42]  G. Zon,et al.  Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. , 1996, Blood.

[43]  B. Calabretta,et al.  The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing. , 1998, Blood.

[44]  Hui-Kuan Lin,et al.  Jak2 is involved in c-Myc induction by Bcr-Abl , 2002, Oncogene.

[45]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[46]  C. Sawyers.  The role of myc in transformation by BCR-ABL. , 1993, Leukemia & lymphoma.

[47]  A. Elmaagacli,et al.  The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage , 2000, Annals of Hematology.

[48]  Kavita Shah,et al.  ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation , 2001, Nature Cell Biology.

[49]  C. Sawyers,et al.  Dominant negative MYC blocks transformation by ABL oncogenes , 1992, Cell.

[50]  D. Shalloway,et al.  An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis , 1994, Nature.

[51]  B. Calabretta,et al.  The biology of CML blast crisis. , 2004, Blood.

[52]  M. Caligiuri,et al.  BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. , 2002, Nature genetics.

[53]  M. Hentze,et al.  c-Src-Mediated Phosphorylation of hnRNP K Drives Translational Activation of Specifically Silenced mRNAs , 2002, Molecular and Cellular Biology.

[54]  A. Bergamaschi,et al.  hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis , 2002, Molecular and Cellular Biology.

[55]  R. Bhatia,et al.  BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. , 2004, Blood.

[56]  P. Raychaudhuri,et al.  trans-Activation by the hnRNP K Protein Involves an Increase in RNA Synthesis from the Reporter Genes (*) , 1996, The Journal of Biological Chemistry.

[57]  S. Tenenbaum,et al.  Ribonomics: identifying mRNA subsets in mRNP complexes using antibodies to RNA-binding proteins and genomic arrays. , 2002, Methods.

[58]  J. Ostrowski,et al.  Regulated Interaction of Protein Kinase Cδ with the Heterogeneous Nuclear Ribonucleoprotein K Protein* , 1999, The Journal of Biological Chemistry.